CompletedPhase 1NCT02057445
3rd Party LMP1/2-Specific Cytotoxic T Lymphocytes for EBV-Associated Lymphoma
Studying Epstein-Barr virus-associated malignant lymphoproliferative disorder
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- New York Medical College
- Principal Investigator
- Mitchell Cairo, MDNew York Medical College
- Intervention
- EBV CTL's(drug)
- Enrollment
- 1 target
- Eligibility
- 1 years · All sexes
- Timeline
- 2014 – 2017
Study locations (2)
- Children's National Medical Center, Washington D.C., District of Columbia, United States
- New York Medical College, Valhalla, New York, United States
Collaborators
Children's National Research Institute · Baylor College of Medicine · M.D. Anderson Cancer Center · University of Michigan · University of Utah · City of Hope Medical Center · Ohio University · Johns Hopkins University
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT02057445 on ClinicalTrials.govOther trials for Epstein-Barr virus-associated malignant lymphoproliferative disorder
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT07381738Unrelated Cord Blood Transplantation for EBV-associated Lymphoproliferative DisordersFudan University
- RECRUITINGPHASE1, PHASE2NCT07450391EBV-AST Cell Injection for EBV-Associated Lymphoproliferative DisordersDaihong Liu
See all trials for Epstein-Barr virus-associated malignant lymphoproliferative disorder →